[Allogenic transplant of non-manipulated hematopoietic progenitor peripheral blood cells. Spanish experience of 79 cases. Allo-Peripheral Blood Transplantation Group].
Brunet
S
S
Urbano-Ispizua
A
A
Solano
C
C
Ojeda
E
E
Caballero
D
D
Torrabadella
M
M
de la Rubia
J
J
Pérez-Oteiza
J
J
Moraleda
J
J
Espigado
I
I
de la Serna
J
J
Petit
J
J
Bargay
J
J
Mataix
R
R
Vivancos
P
P
Figuera
A
A
Sierra
J
J
Domingo-Albós
A
A
Hernández
F
F
García Conde
J
J
Rozman
C
C
D000293:Adolescent; D000328:Adult; D001855:Bone Marrow Diseases / Q000628:therapy; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D007938:Leukemia / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy; D008232:Lymphoproliferative Disorders / Q000628:therapy*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D009101:Multiple Myeloma / Q000628:therapy*; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous
D007166:Immunosuppressive Agents; D016179:Granulocyte Colony-Stimulating Factor; D008727:Methotrexate